Sierra Summit Advisors LLC Makes New $1.11 Million Investment in Theravance Biopharma, Inc. $TBPH

Sierra Summit Advisors LLC acquired a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 59,371 shares of the biopharmaceutical company’s stock, valued at approximately $1,111,000. Sierra Summit Advisors LLC owned 0.12% of Theravance Biopharma at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Theravance Biopharma by 2.5% during the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after buying an additional 54,152 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Theravance Biopharma by 6.2% during the third quarter. Dimensional Fund Advisors LP now owns 766,704 shares of the biopharmaceutical company’s stock worth $11,193,000 after buying an additional 44,634 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Theravance Biopharma during the third quarter worth $10,611,000. UBS Group AG lifted its stake in shares of Theravance Biopharma by 10.9% during the fourth quarter. UBS Group AG now owns 570,425 shares of the biopharmaceutical company’s stock worth $10,673,000 after buying an additional 56,255 shares during the period. Finally, Bank of America Corp DE lifted its stake in shares of Theravance Biopharma by 16.5% during the second quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company’s stock worth $5,952,000 after buying an additional 76,417 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.65% of the company’s stock.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $16.55 on Thursday. The firm has a fifty day moving average price of $15.90 and a 200 day moving average price of $17.52. Theravance Biopharma, Inc. has a 1 year low of $9.10 and a 1 year high of $21.03. The stock has a market cap of $853.15 million, a PE ratio of 7.52 and a beta of 0.19.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The firm had revenue of $17.70 million during the quarter. As a group, equities analysts expect that Theravance Biopharma, Inc. will post 0.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on TBPH shares. B. Riley Financial lifted their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 7th. HC Wainwright lifted their price objective on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings downgraded shares of Theravance Biopharma from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 8th. BTIG Research reiterated a “buy” rating and set a $21.00 price objective on shares of Theravance Biopharma in a research note on Friday, March 20th. Finally, Zacks Research raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $21.83.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.